209733-45-9 Usage
Uses
Used in Pharmaceutical Industry:
Anatibant is used as an anti-inflammatory agent for the treatment of various inflammatory diseases, including acute pancreatitis, arthritis, and other inflammatory disorders. Its mechanism of action involves blocking the binding of bradykinin to its receptor, reducing the inflammatory response and associated pain.
Used in Clinical Trials:
Anatibant is used as a potential therapeutic candidate in clinical trials to evaluate its efficacy and safety in treating inflammatory conditions. Although some promising results have been observed, further research is needed to fully assess its therapeutic potential.
Used in Preclinical Studies:
Anatibant is used as a research tool in preclinical studies to investigate its anti-inflammatory and anti-nociceptive effects. These studies provide valuable insights into its mechanism of action and potential applications in treating inflammatory diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 209733-45-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,9,7,3 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 209733-45:
(8*2)+(7*0)+(6*9)+(5*7)+(4*3)+(3*3)+(2*4)+(1*5)=139
139 % 10 = 9
So 209733-45-9 is a valid CAS Registry Number.
InChI:InChI=1/C34H36Cl2N6O5S/c1-20-18-21(2)41-31-24(20)6-3-8-28(31)47-19-25-26(35)13-14-29(30(25)36)48(45,46)42-17-4-7-27(42)34(44)40-16-5-15-39-33(43)23-11-9-22(10-12-23)32(37)38/h3,6,8-14,18,27H,4-5,7,15-17,19H2,1-2H3,(H3,37,38)(H,39,43)(H,40,44)
209733-45-9Relevant academic research and scientific papers
N-benzenesulfonyl-L-proline derivatives, method for preparing and therapeutic use
-
, (2008/06/13)
PCT No. PCT/FR97/02049 Sec. 371 Date May 6, 1999 Sec. 102(e) Date May 6, 1999 PCT Filed Nov. 14, 1997 PCT Pub. No. WO98/24783 PCT Pub. Date Jun. 11, 1998The present invention relates to compounds selected from the group consisting of (i) the compounds of formula I: in which: X is a halogen atom or a methyl group, A is a group -N(R3)CO- or -CO-N(R3)-, B is a single bond, -CH2- or -CH2-O-, R1 is H, a C1-C3 alkyl group or a CF3 group, R2 and R3 are each independently H or a C1-C3 alkyl group, W is CH or N, and n is 2, 3, 4 or 5; and (ii) their addition salts. It further relates to the process for their preparation and to their use in therapeutics, especially for combating pathological conditions involving bradykinin.
